Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4835639 | 0.98 | OPRM1 (0.43) | OPRM1KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL18339382 | 0.86 | — | — | |
| SCHEMBL9035484 | 0.84 | OPRM1 (0.36) | OPRM1KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL3897731 | 0.76 | KDM4E (0.36) | KMT2AKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL19558970 | 0.75 | — | — | |
| SCHEMBL14232649 | 0.75 | — | — | |
| SCHEMBL5357544 | 0.75 | KDM4E (0.42) | KMT2AKDM4EMEN1ALDH1A1POLB | |
| SCHEMBL248992 | 0.75 | — | — | |
| SCHEMBL5360575 | 0.75 | GRIN2D (0.41) | OPRM1 | |
| SCHEMBL1139911 | 0.75 | KDM4E (0.33) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | claimed |
| WO-2010142650-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | claimed |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | US | claimed |
| EP-1694357-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2006-08-30 | — | — | EP | claimed |
| US-7056915-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | claimed |
| WO-2005058348-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-30 | — | — | WO | claimed |
| US-6787540-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES, ASTHMA, OSTEOPOROSIS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-09-07 | — | — | US | claimed |
| EP-1322613-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-07-02 | — | — | EP | claimed |
| US-20020137932-A1 | Novel compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | claimed |
| WO-2002020485-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | claimed |
| US-11529347-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| US-20190307745-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | disclosed |
| CN-102459162-B | Novel cyclopentane derivatives | HOFFMANN LA ROCHE | 2014-01-08 | — | — | CN | disclosed |
| US-5646172-A | Method of inducing antiandrogenic activity using imidazolidines substituted with a heterocycle | ROUSSEL UCLAF (FR) | 1997-07-08 | — | — | US | disclosed |
| US-5534520-A | Spiro compounds containing five-membered rings | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1996-07-09 | — | — | US | disclosed |
| EP-0711292-A1 | AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY | KOSMIN, Gerald, Emmanuel (GB) | 1996-05-15 | — | — | EP | disclosed |
| EP-0704448-A1 | Heterocyclic substituted imidazolidines, process and intermediates for their preparation, their use as medicaments and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1996-04-03 | — | — | EP | disclosed |
| WO-1995003303-A2 | AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY | STATE OF ISRAEL, REPRESENTED BY THE PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1995-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307745-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN21, PTPN5, PTPN1 | OPRM1 4872/4885KMT2A 758/4885KDM4E 2017/4885 |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | PTPRJ, PTPN2, PTPN5 | OPRM1 4172/4885KMT2A 1636/4885KDM4E 1215/4885 |
| US-11529347-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPN21, PTPN22, PTPN5 | OPRM1 4879/4885KMT2A 919/4885KDM4E 2010/4885 |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | TBXA2R, ADORA1, CNR1 | OPRM1 309/4885KMT2A 4607/4885KDM4E 3982/4885 |
| US-20020137932-A1 | Novel compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | OPRM1 4016/4885KMT2A 4310/4885KDM4E 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.